SB-509 News
Most Popular SB-509 Story
Sangamo buoyed by positive mid-stage data
Shares of Sangamo BioSciences were buoyed by positive preliminary data from a small mid-stage study of SB-509. The drug is being tested as a therapy for severe diabetic neuropathy. In the study, five... Read more...
Latest Headlines
- August 27, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
